[go: up one dir, main page]

HUP0104822A2 - Dehidroepiandroszteron klarátjai és az ezeket tartalmazó gyógyszerkészítmények - Google Patents

Dehidroepiandroszteron klarátjai és az ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0104822A2
HUP0104822A2 HU0104822A HUP0104822A HUP0104822A2 HU P0104822 A2 HUP0104822 A2 HU P0104822A2 HU 0104822 A HU0104822 A HU 0104822A HU P0104822 A HUP0104822 A HU P0104822A HU P0104822 A2 HUP0104822 A2 HU P0104822A2
Authority
HU
Hungary
Prior art keywords
dehydroepiandrosterone
clathrates
clarate
acid
pharmaceutical compositions
Prior art date
Application number
HU0104822A
Other languages
English (en)
Inventor
Paolo Corvi Mora
Original Assignee
Euphar Group S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euphar Group S.R.L. filed Critical Euphar Group S.R.L.
Publication of HUP0104822A2 publication Critical patent/HUP0104822A2/hu
Publication of HUP0104822A3 publication Critical patent/HUP0104822A3/hu
Publication of HU225414B1 publication Critical patent/HU225414B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány dehidroepiandroszteron (DHEA) vagy szulfát formája a-, <-vagy g-ciklodextrin mátrixban kialakuló klarátjára vonatkozik, amelymátrix egy ko-szolubilizálószert, mégpedig egy aminosavat,kroszpovidont, polietilén-glikol 4000-t, cellulózt,karboximetilcellulózt, keményítőt, bórkősavat, borostyánkősavat vagyglutársavat tartalmaz. A találmány kiterjed a fenti klarátgyógyszerkészítmény előállítására történő alkalmazására, valamintmagára a gyógyszerkészítményre is, amely főleg a mellékvesekéregelégtelenségéből, illetve hipogonadizmus eredő rendellenességekkezelésére használható. Ó
HU0104822A 1998-12-18 1999-12-16 Clathrates of dehydroepiandrosterone and pharmaceutical compositions thereof HU225414B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998MI002745A IT1304190B1 (it) 1998-12-18 1998-12-18 Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
PCT/EP1999/010010 WO2000037109A2 (en) 1998-12-18 1999-12-16 Clathrates of dehydroepiandrosterone and corresponding pharmaceutical compositions

Publications (3)

Publication Number Publication Date
HUP0104822A2 true HUP0104822A2 (hu) 2002-05-29
HUP0104822A3 HUP0104822A3 (en) 2002-08-28
HU225414B1 HU225414B1 (en) 2006-11-28

Family

ID=11381280

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104822A HU225414B1 (en) 1998-12-18 1999-12-16 Clathrates of dehydroepiandrosterone and pharmaceutical compositions thereof

Country Status (24)

Country Link
EP (1) EP1140110B1 (hu)
JP (1) JP2002532565A (hu)
KR (1) KR100693514B1 (hu)
CN (1) CN1198620C (hu)
AR (1) AR021663A1 (hu)
AT (1) ATE243517T1 (hu)
AU (1) AU759979B2 (hu)
BR (1) BR9916288A (hu)
CA (1) CA2355148A1 (hu)
CO (1) CO5231137A1 (hu)
DE (1) DE69909128T2 (hu)
DK (1) DK1140110T3 (hu)
EA (1) EA003304B1 (hu)
ES (1) ES2203232T3 (hu)
HU (1) HU225414B1 (hu)
IL (2) IL143776A0 (hu)
IT (1) IT1304190B1 (hu)
NZ (1) NZ512795A (hu)
PE (1) PE20001379A1 (hu)
PT (1) PT1140110E (hu)
TR (1) TR200101766T2 (hu)
TW (1) TWI225791B (hu)
WO (1) WO2000037109A2 (hu)
ZA (1) ZA200105223B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815860B1 (fr) * 2000-10-26 2003-12-12 Oreal Composition, notamment cosmetique, comprenant la dhea et/ou precurseur ou derive de celle-ci et au moins un agent myorelaxant
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
ITMI20021074A1 (it) * 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
ITMI20022549A1 (it) * 2002-12-02 2004-06-03 Actimex S R L Composizione quaternaria comprendente come sostanza attiva la propolis.
BRPI0509583A (pt) * 2004-04-01 2007-10-09 Hoffmann La Roche composições farmacêuticas de pirimidina-2,4,6-trionas
JPWO2006137433A1 (ja) * 2005-06-21 2009-01-22 わかもと製薬株式会社 レボカバスチンを可溶化させた水性薬剤
ITPD20050224A1 (it) * 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
ES2545337T3 (es) * 2011-07-19 2015-09-10 Pantarhei Bioscience B.V. Comprimido que contiene dehidroepiandrosterona (DHEA)
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
EP2986634B1 (en) * 2013-04-19 2019-11-20 University of Houston System Cocrystalline dhea formulations
ES2914305T3 (es) 2017-12-26 2022-06-09 Ind Tech Res Inst Composición para mejorar la solubilidad de sustancias poco solubles, uso de la misma y formulación compleja que contiene la misma
EP3666260A1 (en) 2018-12-13 2020-06-17 Laboratorios Leon Farma SA Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US4978532A (en) * 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5120720A (en) * 1990-09-20 1992-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Preparation of lipophile:hydroxypropylcyclodextrin complexes by a method using co-solubilizers
WO1994004155A1 (en) * 1992-08-19 1994-03-03 Health Resource Institute, Ltd. Dehydroepiandrosterone therapy for the treatment of eye disorders
WO1995015746A1 (en) * 1993-12-10 1995-06-15 The School Of Pharmacy Liposome delivery systems
EP0866722A1 (en) * 1995-11-13 1998-09-30 Supergen, Inc. Improved formulation for administration of steroid compounds

Also Published As

Publication number Publication date
EA200100674A1 (ru) 2001-12-24
WO2000037109A2 (en) 2000-06-29
ES2203232T3 (es) 2004-04-01
CO5231137A1 (es) 2002-12-27
CA2355148A1 (en) 2000-06-29
NZ512795A (en) 2003-08-29
CN1333686A (zh) 2002-01-30
KR20010086109A (ko) 2001-09-07
EP1140110B1 (en) 2003-06-25
ITMI982745A1 (it) 2000-06-18
AU1981000A (en) 2000-07-12
ATE243517T1 (de) 2003-07-15
PT1140110E (pt) 2003-11-28
DE69909128D1 (de) 2003-07-31
IT1304190B1 (it) 2001-03-08
AU759979B2 (en) 2003-05-01
DE69909128T2 (de) 2004-05-06
HUP0104822A3 (en) 2002-08-28
JP2002532565A (ja) 2002-10-02
CN1198620C (zh) 2005-04-27
HU225414B1 (en) 2006-11-28
PE20001379A1 (es) 2000-11-25
DK1140110T3 (da) 2003-10-20
IL143776A0 (en) 2002-04-21
KR100693514B1 (ko) 2007-03-14
IL143776A (en) 2007-03-08
EA003304B1 (ru) 2003-04-24
EP1140110A2 (en) 2001-10-10
TR200101766T2 (tr) 2001-12-21
ZA200105223B (en) 2002-09-25
AR021663A1 (es) 2002-07-31
TWI225791B (en) 2005-01-01
WO2000037109A3 (en) 2000-09-14
BR9916288A (pt) 2001-10-16

Similar Documents

Publication Publication Date Title
HUP0104822A2 (hu) Dehidroepiandroszteron klarátjai és az ezeket tartalmazó gyógyszerkészítmények
CA2370565A1 (en) Dermally applicable vitamin d-containing pharmaceutical compositions
HUP0302499A2 (hu) Ösztrogén-ciklodextrin-komplex tartalmú gyógyászati készítmények és eljárás az előállításukra
DK1157037T3 (da) GCSF-konjugater
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
MY125651A (en) Eplerenone compositions
BG64475B1 (bg) Ципразидонови соли
BRPI0407065A (pt) Composição de pasta de dentes
CA2289202A1 (en) Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent
IL150895A0 (en) Oral, nasal and pulmonary formulations of copolymer-1
NO20006645D0 (no) Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme
DE69803180D1 (de) Ultrafeine-mikrokristalline zellulose-zusammensetzungen und verfahren zu ihrer herstellung
PL373465A1 (en) Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives
TR199700878T1 (xx) Monamin oksidaz B inhibit�rleri i�eren farmakotik kompozisyonlar.
IL139861A0 (en) 17β-AMINO-AND HYDROXYLAMINO -11 β-ARYLSTEROID DERIVATIVES, METHODS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
HUP9903747A2 (hu) Új eljárás mometazon-furoát előállítására
HUP0100333A2 (hu) Tartósítószer rendszer testápolószer számára
HK1024164A1 (en) Use of composition and a cosmetic method for reducing or preventing stinging
WO2000054763A3 (en) Pharmaceutical compositions comprising polymorphic forms of dehydroepiandrosterone
FR2803513B1 (fr) Utilisation de la dhea et/ou de ses precurseurs ou derives pour ameliorer l&#39;aspect papyrace de la peau
ATE338054T1 (de) 17alpha-fluoralkylsteroide, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
HUP0101326A2 (hu) Paroxetinkompozíciók és eljárás az előállításukra
IL129625A0 (en) Novel (-)-enantionmers of CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
MX2022009516A (es) Almidon poroso como agente de carga en gomas de mascar.
YU80700A (sh) Novi 17-halogenizovani 19-nor steroidi, postupak i međuproizvodi za njihovo pripremanje, njihova primena kao medikamenata i farmaceutske kompozicije koje ih sadrže

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees